Patients | ||
Nonsarcoidosis | Sarcoidosis | |
Subjects n | 12 | 14 |
Age yrs | 44.5±11.8 | 45.1±13.4 |
Female | 8 | 6 |
Male | 4 | 8 |
Smoker | 2 | 2 |
Nonsmoker | 10 | 12 |
Cell differentials | ||
Cell number ×106·10−2 mL | 10.1±9.9 | 11.2±8.4 |
Alveolar macrophages % | 96.3±3.3 | 73.1±15.5*** |
Lymphocytes % | 4.6±7.2 | 23.9±14.6*** |
Neutrophils % | 0.9±1.4 | 2.4±2.9 |
Eosinophils % | 0.2±0.5 | 0.7±1.6 |
Lymphocyte subpopulations | ||
CD3 % | 40.0±56.6 | 79.4±11.1 |
CD4 % | 42.0±31.1 | 51.0±14.2 |
CD8 % | 31.5±33.9 | 30.3±11.5 |
CD4/CD8 | 2.2±2.6 | 2.1±1.4 |
IL-2R % | 1.8±1.7 | 1.5±1.2 |
ACE units | 47.7±21.6 | 79.1±35.9 |
HLA-DR % | 4.5±2.1 | 11.6±4.2# |
Functional characteristics | ||
VC % pred | 104.9±21.0 | 85.7±20.6 |
TLC % pred | 99.5±11.9 | 87.7±17.6 |
FEV1/VC % pred | 85.2±5.8 | 78.4±19.9 |
DL,CO % pred | 90.0±27.1 | 64.8±20.8 |
The data are presented as mean±sd unless otherwise stated
IL: interleukin
ACE: angiotensin-converting enzyme
HLA: human lymphocyte antigen
VC: vital capacity
TLC: total lung capacity
FEV1: forced expiratory volume in one second
DL,CO: diffusion capacity for carbon monoxide.
***: p<0.001
#: p<0.02